Allogene Therapeutics Announces Journal of Clinical Oncology Publication of Phase 1 Results of ALLO-316 Highlighting First Durable Remissions Following Allogeneic CAR T for Treatment of Metastatic Solid Tumors

ALLO-316 Achieved a 31% Confirmed Response Rate with the Recommended Phase 2 Regimen in Patients with Stage IV Renal Cell Carcinoma (RCC) with High CD70 Expression

• Single Dose of ALLO-316 Produced Durable Responses in this Cohort with All Responders Progression-Free at the Time of Analysis
• Responses Range from 8 to 18+ Months, with Median Overall Survival Not Yet Reached

Safety Profile was Manageable with Proactive Diagnostic and Management Strategies Effective in Mitigating IEC-HSALLO-316 Demonstrated Robust Expansion and Tumor Infiltration Following Standard Lymphodepletion, Validating the Dagger^® Technology as a Next-Generation Allogeneic CAR T Platform

Excerpt from the Press Release:

SOUTH SAN FRANCISCO, Calif., July 15, 2026 (GLOBE NEWSWIRE) — Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today announced the publication of complete Phase 1 data from the TRAVERSE study of ALLO-316 in advanced or metastatic renal cell carcinoma (RCC) in the Journal of Clinical Oncology. TRAVERSE is being conducted as part of a strategic five-year collaboration with The University of Texas MD Anderson Cancer Center. ALLO-316, Allogene’s CD70-targeting AlloCAR T investigational therapy incorporating the Dagger^® technology, achieved robust expansion, tumor infiltration, and durable antitumor activity in a solid tumor setting.

“TRAVERSE represents a potential breakthrough for both Allogene and the broader CAR T field,” said Zachary Roberts, M.D., Ph.D., President and Chief Executive Officer of Allogene. “CAR T has transformed hematologic malignancies while solid tumors have remained one of the field’s most difficult challenges. When we designed ALLO-316 with the Dagger^® technology, our goal was to address two of the most persistent barriers in solid tumors – achieving robust CAR T expansion with standard lymphodepletion and translating that biology into durable responses. These results show that a well-designed allogeneic CAR T product, developed for a defined population, can expand, persist, and produce durable responses in metastatic, treatment refractory solid tumors. Importantly, the robust CAR T expansion and durable persistence in this trial provides clinical validation of our Dagger^® technology platform and has direct read-through to our broader clinical and preclinical pipeline of next-generation AlloCAR T candidates.”  

Click the button below to read the entire Press Release:

Continue Reading The Press Release